Financials, Business Overview, and Key Risks – Minichart

NIKA PHARMACEUTICALS, INC. 2025 Annual Report: Key Insights for Investors

Nika Pharmaceuticals, Inc. has released its Annual Report for the fiscal year concludeing December 31, 2025. This detailed review highlights crucial information for shareholders and prospective investors, with special attention to developments that may impact share value.

Key Points from the Annual Report

OTCQB Uplisting: On December 9, 2024, Nika Pharmaceuticals’ common stock was uplisted to the OTCQB, marking a significant milestone for the company. Trading on a higher tier may increase visibility, liquidity, and potentially attract institutional investors.
Corporate Structure Changes: On March 4, 2024, the company amconcludeed its Articles of Incorporation, increasing authorized Preferred Stock to 15,000,000 shares. This shift, approved by the Board of Directors (BOD) and shareholders, reflects strategic planning for future capital requireds and flexibility.
Emerging Growth Company Status: Nika qualifies as an “emerging growth company” under the Securities Act and intconcludes to utilize exemptions from certain disclosure requirements, including reduced executive compensation disclosures and auditor attestation requirements. The company has elected to delay adoption of some accounting standards until they apply to private companies.
Stock Issuance: In 2025, Nika issued 17,961,501 shares of common stock as part of its merger with Nika BioTechnology, Inc., out of a total 204,205,027 shares to be issued. Additionally, 200,000 shares were issued to AJO Capital Inc. for services rconcludeered.
Financial Position: As of December 31, 2025, total assets stood at \$20,996, up from \$17,934 in 2024. However, the company reported a substantial stockholders’ deficit of \$297,628, which increased from \$221,230 in the prior year. Accumulated deficit has reached \$9,004,009, highlighting ongoing losses and challenges to profitability.
Going Concern Warning: The report includes a “going concern” qualification from its auditors, citing substantial doubt about the company’s ability to continue as a going concern. The company has not generated income, has significant operating losses, and a working capital deficiency. Management plans to raise additional capital through equity, debt offerings, or borrowings.
Internal Controls: Management has concluded that its disclosure controls and procedures are ineffective, citing material weaknesses such as lack of an audit committee and segregation of duties. No attestation report from the auditor was included, as permitted for emerging growth companies.
Insider Trading Policies: As of December 31, 2025, Nika had not adopted formal written insider trading policies and procedures. Company officers and employees are required to comply with federal securities laws, but formal policies are expected to be implemented as the company grows.
Director and Executive Structure: The company operates with two executive officers: Mr. Dimitar Slavchev Savov (CEO and CFO) and Mr. Clifford P. Redekop (Corporate Secretary). Directors have filed Forms 4 as required for insider transactions.
Compensation and Governance: No code of ethics has been adopted yet, and there is no audit committee or audit committee financial expert. The absence of these governance structures is justified by the company’s early-stage status and simple business affairs, but may raise concerns for investors seeking robust governance.
Dividconclude Policy: The company has not paid dividconcludes and does not expect to do so in the foreseeable future. Future dividconclude policy will depconclude on operational results, financial condition, capital requirements, and investment opportunities.
Equity Compensation Plans: No securities are authorized for issuance under equity compensation plans as of the report date.
Risk Factors: As a compacter reporting company, Nika is not required to disclose risk factors, but acknowledges risks such as economic alters, regulatory shifts, capital availability, competition, and accounting principles.
Material Weaknesses: The report highlights lack of an audit committee and segregation of duties as material weaknesses in internal control over financial reporting, which could adversely affect the company’s ability to record, process, summarize, and report financial data.

Potential Share Price Drivers

OTCQB Uplisting: Increased visibility and liquidity may drive market activity and attract new investors.
Going Concern Warning: Substantial doubt about the company’s ongoing viability is a negative signal and may pressure share prices until resolved.
Large Stock Issuance: The merger-related issuance of new shares may dilute existing shareholders and impact valuation.
Corporate Governance Issues: Lack of audit committee, code of ethics, and formal insider trading policies may concern institutional investors and affect market confidence.
Accumulated Deficit: The sizeable and growing deficit signals ongoing operating losses, which may weigh on investor sentiment.

Important Considerations for Shareholders

Shareholder Dilution: Large issuances of new shares for mergers and service agreements may dilute existing holdings.
Capital Raising Needs: The company intconcludes to seek additional capital, which could result in further dilution or debt.
Governance Risks: Current lack of formal governance structures, audit committee, and insider trading policies may pose risks as the company grows.
Regulatory Compliance: Nika is utilizing emerging growth company exemptions, resulting in reduced transparency for some items.
Market Value Disclosure: The aggregate market value of voting and non-voting common equity held by non-affiliates is disclosed as “N/A,” indicating a lack of market capitalization data.

Conclusion

Nika Pharmaceuticals, Inc. remains an early-stage, emerging growth company with ambitious plans for expansion. However, key risks—including substantial operating losses, a growing deficit, governance gaps, and a “going concern” warning—are likely to influence share price and investor sentiment. The uplisting to OTCQB may be a positive catalyst, but investors should consider the risks and uncertainties outlined in this report before creating investment decisions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial or legal advisors before creating investment decisions. The information presented is based on the company’s 2025 Annual Report and may be subject to alter.